Connect with us

Coronavirus

WHO insists on its COVID-19 transmission guidance despite US new draft change

WHO has once again dismissed warnings by the United States’ CDC that the Coronavirus could be transmitted through airborne particles.

Published

on

The World Health Organization (WHO) disclosed on Monday that it has not changed its policy on the aerosol transmission of the coronavirus disease, after United States health officials mistakenly drafted new guidance, warning that it could be transmitted through airborne particles.

While making the disclosure in a press briefing, the Executive Director of WHO’s Emergency Programme, Mike Ryan, said that he would follow up with the US Centers for Disease Control and Prevention (CDC) in the next 24 hours, after it said COVID-19 could spread through airborne particles that could remain suspended in the air and travel beyond six feet.

In a briefing, Mike Ryan said, “Certainly we haven’t seen any new evidence and our position on this remains the same.”

Themoneymetrics had earlier reported that the WHO while providing an update on the mode of transmission of SARS-CoV-2 (the virus that caused the Covid-19) from infected people, revealed that based on new scientific evidence, the coronavirus can be transmitted indoors by droplets in the air.

The UN health agency, in a scientific brief, said that people who spend time in crowded places with poor ventilation are at risk of being infected by the coronavirus as the droplets circulate throughout the air in indoor gatherings.

The CDC said that a draft version of changes to its recommendations were posted in error on its website, while it was in the process of updating its guidance.

It, however, said that the guidance would be reposted as soon as it had completed the review.

The CDC previously disclosed that the virus mainly spread from person to person through respiratory droplets when a sick person coughed, sneezed or talked.

The WHO’s Ryan said the agency still believesthe disease is primarily spread through droplets, but that in crowded closed spaces with inadequate ventilation, aerosol transmission can occur.

He said, “We still, based on the evidence, believe that there is a wide range of transmission modes.”

Advertisement
Click to comment

Leave a Reply

Coronavirus

US Tennis player Sam Querrey accused of fleeing Russia on private jet after testing positive for COVID-19

Published

on

33 year old US tennis player Sam Querrey, has been accused of fleeing Russia on a private jet after he and his family tested positive for Covid-19.

Querrey and his wife had tested positive for the virus ahead of the St. Petersburg Open this week and were placed in quarantine at a  hotel, according to the tournament organizers.

Doctors had recommended Querrey and his family be moved to a private apartment but he did not allegedly answer the door when doctors were dispatched to evaluate his condition.

“Sam Querrey was scheduled to retest on Thursday, October 15, however, instead of acting in accordance with ATP rules and the tournament’s sanitary protocol, Sam Querrey was recorded leaving the hotel by hotel security cameras at 5.45 a.m. on October 13, with his family, without notifying the reception,”

“As Querrey told the ATP representative, he and his family left Russia on a private plane.” read a statement from organizers.

The ATP which is the World tennis controlling body, said it was aware of an incident “regarding a player’s serious breach of protocol”

Querrey has not won a grand slam singles title in his career but is ranked world number 47.

Querrey has not responded to the allegations as at press time.

Continue Reading

Coronavirus

WHO study reveals new discovery about remdesivir drug’s effect on Covid-19 patients

The study found that the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course.

Published

on

A World Health Organization (WHO) study has discovered that Gilead Sciences Inc’s remdesivir had little or no effect on COVID-19 patients’ length of stay in the hospital or chances of survival.

The only antiviral drug authorized for treatments of Covid-19 in the US failed to prevent deaths among patients.

The antiviral medication, among the first to be used as a treatment for COVID-19, was one of the drugs recently used to treat U.S. President Donald Trump’s coronavirus infection.

The results are from WHO’s Solidarity trial, which evaluated the effects of 4 potential drug regimens, including remdesivir, hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir and interferon, in 11,266 adult patients across more than 30 countries.

The study found that the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course among patients hospitalized with COVID-19, the WHO said on Thursday.

The results of the trial, which were posted online on Thursday, October 15, 2020, are yet to be peer-reviewed or published in a scientific journal

Earlier this month, data from a U.S. study of remdesivir by Gilead showed that the treatment cut COVID-19 recovery time by five days compared with patients who got a placebo in a trial comprising 1,062 patients.

Gilead told Reuters, “The emerging (WHO) data appears inconsistent, with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of remdesivir.

“We are concerned the data from this open-label global trial has not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design.”

Remdesivir, which was originally developed as a treatment for Ebola and Hepatitis C, interferes with the reproduction of viruses by jamming itself into new viral genes.

WHO chief scientist Soumya Swaminathan said on Wednesday that during the study, hydroxychloroquine and lopinavir/ritonavir were stopped in June after they proved ineffective, but other trials continued in more than 500 hospitals and 30 countries.

Swaminathan said, “We’re looking at what’s next. We’re looking at monoclonal anti-bodies, we’re looking at immunomodulators and some of the newer anti-viral drugs that have been developed in the last few months.”

Remdesivir received emergency use authorization from the U.S. Food and Drug Administration on May 1, and has since been authorized for use in several countries.

Gilead, however, disputed the conclusions of the W.H.O. study on Thursday, noting that a variety of drugs and drug combinations had been evaluated under a wide range of circumstances and that more rigorous studies had found a benefit.

Continue Reading

Coronavirus

148 new cases of Coronavirus recorded in Nigeria

On the 15th of October 2020, 148 new confirmed cases were recorded in Nigeria

Published

on

148 new cases of Coronavirus were recorded in Nigerian on Thursday October 15, as confirmed by the Nigeria Centre for Disease Control (NCDC).

A breakdown of the new cases is as follows; Lagos (66), FCT (25), Oyo (13), Plateau (11), Kaduna (7), Rivers (6), Ebonyi (5), Ekiti (4), Ogun (4), Imo (2), Ondo (2), Edo (1), Nasarawa (1), Taraba (1).

A total of 60,982 cases have been confirmed in the country, 52,194 cases have been discharged and 1,116 deaths have been recorded in 36 states and the Federal Capital Territory.

Continue Reading
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement

Follow us on Twitter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 87 other subscribers

Trending